Clinical Trial Update: Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) [Phase 3]

View source ↗

Summary

A Phase 3 placebo-controlled study of BG00012 (dimethyl fumarate) in pediatric relapsing-remitting multiple sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Forms of Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tecfidera (dimethyl fumarate)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis | Phase 3 | Status: WITHDRAWN